IMANIB 400 MG

Imatinib mesylate is the mesylate form represented in this database for a targeted tyrosine-kinase inhibitor with activity against BCR-ABL, KIT, and PDGFRA. That target profile gives the medicine a distinctive role across both hematologic and solid tumors. The listed indications include chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia, KIT-positive gastrointestinal stromal tumor, and selected PDGFRA/KIT-driven tumors. Unlike a conventional cytotoxic agent, its clinical positioning is closely tied to the molecular driver or receptor identified in the disease. The regimen field includes single-agent treatment, adjuvant therapy for GIST, and Philadelphia chromosome-positive leukemia protocols. These entries demonstrate how the same molecular inhibitor can be used in different treatment settings when the relevant target is present. The mesylate designation does not represent a different mechanism from imatinib; it is the specific form/name retained in the source list. Eligibility should be interpreted from the disease-specific indication and current regulatory labeling rather than from the generic drug class alone. This reference description does not supply individualized dosing or treatment instructions. The target-driven nature of these uses is the main clinical distinction from broadly acting cytotoxic chemotherapy.